Medtronic: FY26 Outlook Strengthened By New Product Launches

Core Viewpoint - Medtronic (NYSE: MDT) shares are currently considered undervalued, presenting an attractive buying opportunity due to the company's steady growth, marking the last quarter as the 11th consecutive quarter of growth [1]. Company Performance - Medtronic has demonstrated consistent growth over the past 11 quarters, indicating a stable performance trajectory [1].